CA3044593A1 - Compositions and methods for tcr reprogramming using fusion proteins - Google Patents
Compositions and methods for tcr reprogramming using fusion proteins Download PDFInfo
- Publication number
- CA3044593A1 CA3044593A1 CA3044593A CA3044593A CA3044593A1 CA 3044593 A1 CA3044593 A1 CA 3044593A1 CA 3044593 A CA3044593 A CA 3044593A CA 3044593 A CA3044593 A CA 3044593A CA 3044593 A1 CA3044593 A1 CA 3044593A1
- Authority
- CA
- Canada
- Prior art keywords
- domain
- tcr
- tfp
- nucleic acid
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 103
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 103
- 238000000034 method Methods 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title description 2
- 230000008672 reprogramming Effects 0.000 title description 2
- 108091008874 T cell receptors Proteins 0.000 claims abstract description 1204
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims abstract description 1204
- 239000000427 antigen Substances 0.000 claims abstract description 200
- 108091007433 antigens Proteins 0.000 claims abstract description 200
- 102000036639 antigens Human genes 0.000 claims abstract description 200
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 171
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 38
- 201000010099 disease Diseases 0.000 claims abstract description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 35
- 201000011510 cancer Diseases 0.000 claims abstract description 24
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 422
- 108020004707 nucleic acids Proteins 0.000 claims description 422
- 150000007523 nucleic acids Chemical class 0.000 claims description 420
- 230000027455 binding Effects 0.000 claims description 390
- 241000282414 Homo sapiens Species 0.000 claims description 276
- 230000003834 intracellular effect Effects 0.000 claims description 174
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 162
- 229920001184 polypeptide Polymers 0.000 claims description 161
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 161
- 239000012634 fragment Substances 0.000 claims description 147
- 210000004027 cell Anatomy 0.000 claims description 128
- 239000003446 ligand Substances 0.000 claims description 126
- 230000004068 intracellular signaling Effects 0.000 claims description 96
- 150000001413 amino acids Chemical group 0.000 claims description 95
- 239000013598 vector Substances 0.000 claims description 86
- 230000004048 modification Effects 0.000 claims description 85
- 238000012986 modification Methods 0.000 claims description 85
- 230000004936 stimulating effect Effects 0.000 claims description 73
- 102000004169 proteins and genes Human genes 0.000 claims description 70
- 108090000623 proteins and genes Proteins 0.000 claims description 70
- 241000124008 Mammalia Species 0.000 claims description 57
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 56
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 56
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 48
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 48
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 48
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 43
- 108010073807 IgG Receptors Proteins 0.000 claims description 30
- 102000009490 IgG Receptors Human genes 0.000 claims description 30
- 230000014509 gene expression Effects 0.000 claims description 29
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 26
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 25
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 22
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 22
- 102000005962 receptors Human genes 0.000 claims description 20
- 108020003175 receptors Proteins 0.000 claims description 20
- -1 CD86 Proteins 0.000 claims description 19
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 18
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 18
- 239000000539 dimer Substances 0.000 claims description 18
- 239000000178 monomer Substances 0.000 claims description 18
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 17
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 17
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 17
- 108010006700 Receptor Tyrosine Kinase-like Orphan Receptors Proteins 0.000 claims description 17
- 230000011664 signaling Effects 0.000 claims description 17
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 16
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 claims description 15
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 15
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 15
- 230000000139 costimulatory effect Effects 0.000 claims description 15
- 102000004127 Cytokines Human genes 0.000 claims description 12
- 108090000695 Cytokines Proteins 0.000 claims description 12
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 12
- 102000044042 human KLRK1 Human genes 0.000 claims description 12
- 238000000338 in vitro Methods 0.000 claims description 12
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 10
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 10
- 101001132524 Homo sapiens Retinoic acid early transcript 1E Proteins 0.000 claims description 10
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims description 10
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims description 10
- 108010073816 IgE Receptors Proteins 0.000 claims description 10
- 102000009438 IgE Receptors Human genes 0.000 claims description 10
- 102100033964 Retinoic acid early transcript 1E Human genes 0.000 claims description 10
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims description 10
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims description 10
- 239000013638 trimer Substances 0.000 claims description 10
- 108010065816 zeta chain antigen T cell receptor Proteins 0.000 claims description 10
- 102000003886 Glycoproteins Human genes 0.000 claims description 9
- 108090000288 Glycoproteins Proteins 0.000 claims description 9
- 108091005804 Peptidases Proteins 0.000 claims description 9
- 239000004365 Protease Substances 0.000 claims description 9
- 238000003776 cleavage reaction Methods 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 230000007017 scission Effects 0.000 claims description 9
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 8
- 102000043129 MHC class I family Human genes 0.000 claims description 8
- 108091054437 MHC class I family Proteins 0.000 claims description 8
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 8
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 6
- 108020004414 DNA Proteins 0.000 claims description 6
- 101000607306 Homo sapiens UL16-binding protein 1 Proteins 0.000 claims description 6
- 101000607320 Homo sapiens UL16-binding protein 2 Proteins 0.000 claims description 6
- 101000607318 Homo sapiens UL16-binding protein 3 Proteins 0.000 claims description 6
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 6
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 108091036407 Polyadenylation Proteins 0.000 claims description 6
- 102100040012 UL16-binding protein 1 Human genes 0.000 claims description 6
- 102100039989 UL16-binding protein 2 Human genes 0.000 claims description 6
- 102100040011 UL16-binding protein 3 Human genes 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 6
- 230000036210 malignancy Effects 0.000 claims description 6
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- 102100037904 CD9 antigen Human genes 0.000 claims description 5
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 claims description 5
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims description 5
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 claims description 5
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 claims description 5
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 5
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 5
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 claims description 5
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 claims description 5
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 claims description 5
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 5
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 5
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 5
- 101000607316 Homo sapiens UL-16 binding protein 5 Proteins 0.000 claims description 5
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 claims description 5
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 5
- 108020003285 Isocitrate lyase Proteins 0.000 claims description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 5
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 5
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 5
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims description 5
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 claims description 5
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 claims description 5
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 5
- 102000016978 Orphan receptors Human genes 0.000 claims description 5
- 108070000031 Orphan receptors Proteins 0.000 claims description 5
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 5
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 5
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 5
- 102100040010 UL-16 binding protein 5 Human genes 0.000 claims description 5
- 230000005809 anti-tumor immunity Effects 0.000 claims description 5
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 5
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 5
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 5
- 230000005754 cellular signaling Effects 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 230000003211 malignant effect Effects 0.000 claims description 5
- 239000010445 mica Substances 0.000 claims description 5
- 229910052618 mica group Inorganic materials 0.000 claims description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 101710160107 Outer membrane protein A Proteins 0.000 claims description 4
- 230000003938 response to stress Effects 0.000 claims description 4
- 102100027207 CD27 antigen Human genes 0.000 claims description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 3
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 3
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 3
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 3
- 241000713666 Lentivirus Species 0.000 claims description 3
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 3
- 230000000735 allogeneic effect Effects 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000035800 maturation Effects 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 238000012163 sequencing technique Methods 0.000 claims description 3
- 230000002463 transducing effect Effects 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 102000000812 NK Cell Lectin-Like Receptor Subfamily K Human genes 0.000 claims description 2
- 108010001657 NK Cell Lectin-Like Receptor Subfamily K Proteins 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 18
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 13
- 201000003444 follicular lymphoma Diseases 0.000 claims 12
- 125000003729 nucleotide group Chemical group 0.000 claims 12
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 8
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 7
- 206010033128 Ovarian cancer Diseases 0.000 claims 7
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 6
- 208000007541 Preleukemia Diseases 0.000 claims 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 6
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 5
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims 4
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 4
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 4
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 4
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 4
- 208000016778 CD4+/CD56+ hematodermic neoplasm Diseases 0.000 claims 4
- 239000005977 Ethylene Substances 0.000 claims 4
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 claims 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 4
- 201000003791 MALT lymphoma Diseases 0.000 claims 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 4
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 4
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 4
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 4
- 208000035269 cancer or benign tumor Diseases 0.000 claims 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 201000009277 hairy cell leukemia Diseases 0.000 claims 4
- 230000001589 lymphoproliferative effect Effects 0.000 claims 4
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 4
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 4
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 4
- 208000007525 plasmablastic lymphoma Diseases 0.000 claims 4
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 2
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 claims 2
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 claims 2
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims 2
- 206010058314 Dysplasia Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims 2
- 206010061328 Ovarian epithelial cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 201000008274 breast adenocarcinoma Diseases 0.000 claims 2
- 208000018463 endometrial serous adenocarcinoma Diseases 0.000 claims 2
- 208000028653 esophageal adenocarcinoma Diseases 0.000 claims 2
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 claims 2
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 2
- 208000013371 ovarian adenocarcinoma Diseases 0.000 claims 2
- 201000006588 ovary adenocarcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 201000001531 bladder carcinoma Diseases 0.000 claims 1
- 201000008275 breast carcinoma Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005296 lung carcinoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000001514 prostate carcinoma Diseases 0.000 claims 1
- 201000010174 renal carcinoma Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 83
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 83
- 125000003275 alpha amino acid group Chemical group 0.000 description 53
- 235000018102 proteins Nutrition 0.000 description 23
- 229920002477 rna polymer Polymers 0.000 description 8
- 238000002619 cancer immunotherapy Methods 0.000 description 6
- 102220241871 rs140296303 Human genes 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 108091008034 costimulatory receptors Proteins 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000008004 immune attack Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000011301 standard therapy Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000003735 Mesothelin Human genes 0.000 description 1
- 108090000015 Mesothelin Proteins 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2836—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD106
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662425535P | 2016-11-22 | 2016-11-22 | |
| US201662425407P | 2016-11-22 | 2016-11-22 | |
| US62/425,535 | 2016-11-22 | ||
| US62/425,407 | 2016-11-22 | ||
| US201662425697P | 2016-11-23 | 2016-11-23 | |
| US201662425884P | 2016-11-23 | 2016-11-23 | |
| US62/425,884 | 2016-11-23 | ||
| US62/425,697 | 2016-11-23 | ||
| PCT/US2017/063137 WO2018098365A2 (en) | 2016-11-22 | 2017-11-22 | Compositions and methods for tcr reprogramming using fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3044593A1 true CA3044593A1 (en) | 2018-05-31 |
Family
ID=60655125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3044593A Pending CA3044593A1 (en) | 2016-11-22 | 2017-11-22 | Compositions and methods for tcr reprogramming using fusion proteins |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11851491B2 (OSRAM) |
| EP (1) | EP3544996A2 (OSRAM) |
| JP (2) | JP7291396B2 (OSRAM) |
| CN (1) | CN110177803A (OSRAM) |
| AU (1) | AU2017363311A1 (OSRAM) |
| CA (1) | CA3044593A1 (OSRAM) |
| WO (1) | WO2018098365A2 (OSRAM) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3298033T4 (da) | 2015-05-18 | 2023-10-02 | Tcr2 Therapeutics Inc | Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner |
| JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法 |
| CA3036745A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| JP2020506971A (ja) | 2017-02-08 | 2020-03-05 | ドラゴンフライ セラピューティクス， インコーポレイテッド | ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用 |
| SG11201907646YA (en) | 2017-02-20 | 2019-09-27 | Dragonfly Therapeutics Inc | Proteins binding her2, nkg2d and cd16 |
| MX420947B (es) | 2017-04-26 | 2025-02-10 | Eureka Therapeutics Inc | Constructos que reconocen específicamente glipicano 3 y usos de estos. |
| IL310182A (en) | 2017-04-26 | 2024-03-01 | Eureka Therapeutics Inc ׂ A Delaware Corp | Structures of chimeric antibody/T-cell receptor and uses thereof |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| FI3749346T3 (fi) | 2018-02-08 | 2024-09-04 | Dragonfly Therapeutics Inc | Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät |
| PE20210375A1 (es) | 2018-02-08 | 2021-03-02 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales |
| AU2019222560B2 (en) | 2018-02-17 | 2025-07-03 | Flagship Pioneering Innovations V, Inc. | Compositions and methods for membrane protein delivery |
| MX2020008684A (es) | 2018-02-20 | 2020-12-07 | Dragonfly Therapeutics Inc | Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso. |
| WO2019173693A1 (en) * | 2018-03-09 | 2019-09-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| WO2019242632A1 (en) * | 2018-06-19 | 2019-12-26 | 1§1Nanjing Legend Biotech Co., Ltd. | Engineered cells and uses thereof |
| CN112955465A (zh) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| JP2021530503A (ja) * | 2018-07-26 | 2021-11-11 | ティーシーアール２ セラピューティクス インク． | 標的特異的融合タンパク質を使用してｔｃｒをリプログラミングするための組成物及び方法 |
| US12384851B2 (en) * | 2018-08-08 | 2025-08-12 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use |
| JP7482363B2 (ja) | 2018-08-08 | 2024-05-14 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及び腫瘍関連抗原に結合するタンパク質 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| WO2020072536A1 (en) * | 2018-10-01 | 2020-04-09 | Adicet Bio, Inc. | COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON- ENGINEERED γδ-Τ CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS |
| CN113631718A (zh) | 2018-11-14 | 2021-11-09 | 旗舰先锋创新V股份有限公司 | 用于特定隔室货物递送的组合物和方法 |
| CN109627340B (zh) * | 2018-12-05 | 2021-02-12 | 上海交通大学 | Cd3和prlr双特异性抗体及其构建与应用 |
| GB2595980B (en) * | 2019-01-04 | 2023-06-14 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| JP7710373B2 (ja) | 2019-02-21 | 2025-07-18 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| WO2020172605A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| US20220175833A1 (en) * | 2019-03-07 | 2022-06-09 | Children's Medical Center Corporation | Targeted delivery of immune-modulating vhh and vhh-fusion protein |
| EP3715368A1 (en) | 2019-03-28 | 2020-09-30 | Albert-Ludwigs-Universität Freiburg | Chimeric antigen receptors, vectors coding for such receptors and their use in the modification of t cells |
| WO2020201527A1 (en) | 2019-04-04 | 2020-10-08 | Umc Utrecht Holding B.V. | Modified immune receptor constructs |
| US20220177912A1 (en) * | 2019-04-12 | 2022-06-09 | The Methodist Hospital | Therapeutic particles that enable antigen presenting cells to attack cancer cells |
| CN113728095A (zh) * | 2019-04-22 | 2021-11-30 | 南京传奇生物科技有限公司 | 工程化的细胞及其用途 |
| AU2020325225A1 (en) * | 2019-08-05 | 2022-03-24 | Cartherics Pty. Ltd. | Immune cells expressing modified cell receptors and methods of making |
| CN114615886A (zh) * | 2019-08-29 | 2022-06-10 | 得克萨斯大学体系董事会 | 细胞冷冻保存培养基 |
| BR112022004458A2 (pt) * | 2019-09-12 | 2022-05-31 | Tcr2 Therapeutics Inc | Composições e métodos para reprogramação de tcr usando proteínas de fusão |
| CN112500492B (zh) * | 2019-09-13 | 2023-08-04 | 中国科学院分子细胞科学卓越创新中心 | 一种嵌合抗原受体及其用途 |
| CA3166629A1 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| WO2021155034A1 (en) * | 2020-01-29 | 2021-08-05 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using muc16 specific fusion proteins |
| AU2021237570A1 (en) * | 2020-03-16 | 2022-09-08 | Angeles Therapeutics, Inc. | Novel antigen binding domains and synthetic antigen receptors incorporating the same |
| WO2021226289A2 (en) * | 2020-05-05 | 2021-11-11 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using cd70 specific fusion proteins |
| TW202208428A (zh) | 2020-05-06 | 2022-03-01 | 美商蜻蜓醫療公司 | 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質 |
| US20230220419A1 (en) * | 2020-05-27 | 2023-07-13 | The Medical College Of Wisconsin, Inc. | Improved Lentiviral Vector Transfer Plasmid and Methods of Use |
| CN113980136B (zh) * | 2020-07-27 | 2023-08-22 | 中国科学院分子细胞科学卓越创新中心 | 一种包含具有Y/F突变的CD3ε胞内区的嵌合抗原受体及其用途 |
| CN111995689B (zh) * | 2020-08-27 | 2023-05-05 | 深圳市体内生物医药科技有限公司 | 一种基因修饰的免疫细胞及其制备方法和应用 |
| CA3197321A1 (en) * | 2020-09-29 | 2022-04-07 | NeuExcell Therapeutics Inc. | Neurod1 vector |
| WO2022072325A1 (en) * | 2020-09-29 | 2022-04-07 | NeuExcell Therapeutics Inc. | Neurod1 combination vector |
| US20220098616A1 (en) * | 2020-09-29 | 2022-03-31 | NeuExcell Therapeutics Inc. | ISL1 and LHX3 VECTOR |
| AU2021410788A1 (en) * | 2020-12-23 | 2023-08-03 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2022147481A1 (en) | 2020-12-30 | 2022-07-07 | Ansun Biopharma Inc. | Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen |
| CN114957481A (zh) * | 2021-02-25 | 2022-08-30 | 华夏英泰（北京）生物技术有限公司 | 针对cd19和cd22的双靶点star |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| WO2023010436A1 (zh) * | 2021-08-05 | 2023-02-09 | 卡瑞济(北京)生命科技有限公司 | Tcr表达构建体以及其制备方法和用途 |
| CN115806625B (zh) * | 2021-09-15 | 2023-08-04 | 广州百暨基因科技有限公司 | T细胞限定表达的嵌合抗原受体及其应用 |
| JP2024540099A (ja) | 2021-10-28 | 2024-10-31 | ライエル・イミュノファーマ・インコーポレイテッド | Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法 |
| WO2023081767A1 (en) | 2021-11-05 | 2023-05-11 | Precision Biosciences, Inc. | Methods for immunotherapy |
| WO2023091910A1 (en) | 2021-11-16 | 2023-05-25 | Precision Biosciences, Inc. | Methods for cancer immunotherapy |
| WO2023108150A1 (en) | 2021-12-10 | 2023-06-15 | Precision Biosciences, Inc. | Methods for cancer immunotherapy |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| CN120435501A (zh) * | 2022-12-30 | 2025-08-05 | 上药生物治疗（香港）有限公司 | 细胞原位分泌抗体及其用途 |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
Family Cites Families (252)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5906936A (en) | 1988-05-04 | 1999-05-25 | Yeda Research And Development Co. Ltd. | Endowing lymphocytes with antibody specificity |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| IL104570A0 (en) * | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| WO1993019163A1 (en) | 1992-03-18 | 1993-09-30 | Yeda Research And Development Co, Ltd. | Chimeric receptor genes and cells transformed therewith |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| GB9809658D0 (en) | 1998-05-06 | 1998-07-01 | Celltech Therapeutics Ltd | Biological products |
| US7081518B1 (en) | 1999-05-27 | 2006-07-25 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-mesothelin antibodies having high binding affinity |
| JP2003502341A (ja) | 1999-06-16 | 2003-01-21 | マイアロス コーポレイション | 白血病阻害因子に由来するレトロ−インベルソなペプチド |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| AU2001271589A1 (en) | 2000-06-30 | 2002-01-14 | Zymogenetics Inc. | Mammalian secreted proteins |
| JP5312721B2 (ja) | 2000-11-07 | 2013-10-09 | シティ・オブ・ホープ | Ｃｄ１９特異的再指向免疫細胞 |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| US7371849B2 (en) | 2001-09-13 | 2008-05-13 | Institute For Antibodies Co., Ltd. | Methods of constructing camel antibody libraries |
| EP1474451A2 (en) | 2002-02-13 | 2004-11-10 | Micromet AG | De-immunized (poly)peptide constructs |
| DE10244457A1 (de) | 2002-09-24 | 2004-04-01 | Johannes-Gutenberg-Universität Mainz | Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren |
| NZ540196A (en) | 2002-11-08 | 2008-09-26 | Ablynx Nv | Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| US7251470B2 (en) | 2003-06-25 | 2007-07-31 | Nokia Corporation | Emergency response system with personal emergency device |
| AU2004255216B2 (en) | 2003-07-01 | 2010-08-19 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| WO2005042743A2 (en) | 2003-08-18 | 2005-05-12 | Medimmune, Inc. | Humanization of antibodies |
| CA2537055A1 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
| US8076459B2 (en) | 2003-10-16 | 2011-12-13 | Micromet Ag | Multispecfic deimmunized CD3-binders |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| ATE468356T1 (de) | 2003-11-25 | 2010-06-15 | Us Gov Health & Human Serv | Mutierte anti-cd22-antikörper und immunkonjugate |
| US20050238626A1 (en) | 2004-04-01 | 2005-10-27 | Lili Yang | Antigen specific T cell therapy |
| EP1786918A4 (en) | 2004-07-17 | 2009-02-11 | Imclone Systems Inc | NEW BISPECIFIC ANTIBODY TETRAVALENT |
| WO2006018833A2 (en) | 2004-08-16 | 2006-02-23 | Tadiran Spectralink Ltd. | A wearable device, system and method for measuring a pulse while a user is in motion |
| US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| AU2006223301B2 (en) | 2005-03-10 | 2010-11-04 | Eisai, Inc. | Anti-mesothelin antibodies |
| WO2006124641A2 (en) | 2005-05-12 | 2006-11-23 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health | Anti-mesothelin antibodies useful for immunological assays |
| EP2500352A1 (en) | 2005-08-19 | 2012-09-19 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| AT503861B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| JP5840837B2 (ja) | 2007-03-30 | 2016-01-06 | メモリアル スローン−ケタリング キャンサー センター | 養子移入ｔリンパ球における副刺激リガンドの構成性発現 |
| GB0721686D0 (en) * | 2007-11-05 | 2007-12-12 | Medinnova As | Polypeptides |
| MX2010005603A (es) | 2007-11-26 | 2010-08-02 | Bayer Schering Pharma Ag | Anticuerpos antimesotelina y usos de los mismos. |
| EP2225275A4 (en) | 2007-11-28 | 2013-04-03 | Medimmune Llc | PROTEIN FORMULATION |
| KR20090092900A (ko) | 2008-02-28 | 2009-09-02 | 신준호 | 어린이 및 노약자 안전보호시스템 |
| US20090322513A1 (en) | 2008-06-27 | 2009-12-31 | Franklin Dun-Jen Hwang | Medical emergency alert system and method |
| WO2010025177A1 (en) | 2008-08-26 | 2010-03-04 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| AU2009290543B2 (en) | 2008-09-12 | 2015-09-03 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| AU2009299791B2 (en) | 2008-10-01 | 2016-02-25 | Amgen Research (Munich) Gmbh | Cross-species-specific PSCAxCD3, CD19xCD3, C-METxCD3, EndosialinxCD3, EpCAMxC D3, IGF-1RxCD3 or FAPalpha xCD3 bispecific single chain antibody |
| HUE028175T2 (en) | 2008-11-07 | 2016-12-28 | Amgen Res Munich Gmbh | Treatment of acute lymphoblastic leukemia |
| CN102421800A (zh) | 2009-02-23 | 2012-04-18 | 格兰马克药品股份有限公司 | 结合cd19的人源化抗体及其用途 |
| NZ594985A (en) | 2009-03-10 | 2013-07-26 | Biogen Idec Inc | Anti-bcma (b-cell maturation antigen, cd269, tnfrsf17) antibodies |
| EP2421899B1 (en) | 2009-04-23 | 2016-06-08 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-human ror1 antibodies |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| EP3260092A1 (en) | 2009-10-23 | 2017-12-27 | Nexisvision, Inc. | Corneal denervation for treatment of ocular pain |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| PT2361936T (pt) | 2010-02-25 | 2016-07-15 | Affimed Gmbh | Molécula que se liga a antigénio e utilizações desta |
| PL2552959T3 (pl) | 2010-03-26 | 2017-08-31 | Memorial Sloan-Kettering Cancer Center | Przeciwciała przeciwko MUC16 i metody stosowania |
| WO2012008860A2 (en) | 2010-07-16 | 2012-01-19 | Auckland Uniservices Limited | Bacterial nitroreductase enzymes and methods relating thereto |
| EP3467101A3 (en) | 2010-09-08 | 2019-06-19 | Baylor College of Medicine | Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells |
| HUE048639T2 (hu) | 2010-10-27 | 2020-08-28 | Amgen Res Munich Gmbh | Eljárás DLBCL kezelésére |
| NZ609967A (en) | 2010-10-27 | 2015-04-24 | Baylor College Medicine | Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies |
| CA2818992C (en) | 2010-12-01 | 2021-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric rabbit/human ror1 antibodies |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| GB201020995D0 (en) | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| EP3296321B1 (en) | 2010-12-20 | 2020-07-15 | F. Hoffmann-La Roche AG | Anti-mesothelin antibodies and immunoconjugates |
| WO2012097313A2 (en) | 2011-01-14 | 2012-07-19 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
| AU2012207356A1 (en) | 2011-01-18 | 2013-08-01 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| JP5955871B2 (ja) | 2011-03-17 | 2016-07-20 | ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｔｃｒアルファ／ベータを枯渇させた細胞調製物 |
| PL2694549T3 (pl) | 2011-04-08 | 2019-01-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeryczne receptory antygenowe anty-wariant III receptora czynnika wzrostu naskórka i ich zastosowanie do leczenia raka |
| EA201490364A1 (ru) | 2011-07-29 | 2014-08-29 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Костимулирующие рецепторы-переключатели |
| WO2013040557A2 (en) | 2011-09-16 | 2013-03-21 | The Trustees Of The University Of Pennsylvania | Rna engineered t cells for the treatment of cancer |
| KR101471647B1 (ko) | 2011-10-26 | 2014-12-11 | 국립암센터 | 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물 |
| US9272002B2 (en) | 2011-10-28 | 2016-03-01 | The Trustees Of The University Of Pennsylvania | Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
| WO2013067492A1 (en) | 2011-11-03 | 2013-05-10 | The Trustees Of The University Of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
| US20140322216A1 (en) | 2011-11-08 | 2014-10-30 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| CN104159909A (zh) | 2012-02-22 | 2014-11-19 | 宾夕法尼亚大学董事会 | 产生用于癌症治疗的t细胞持续性群体的组合物和方法 |
| ES2959443T3 (es) | 2012-02-22 | 2024-02-26 | Univ Pennsylvania | Uso del dominio de señalización de CD2 en receptores de antígenos quiméricos de segunda generación |
| EP2828290B1 (en) | 2012-03-23 | 2018-08-15 | The United States of America, represented by the Secretary, Department of Health and Human Services | Anti-mesothelin chimeric antigen receptors |
| KR102086874B1 (ko) | 2012-04-11 | 2020-03-10 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | B-세포 성숙 항원을 표적화하는 키메라 항원 수용체 |
| US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| CN111676196A (zh) | 2012-05-25 | 2020-09-18 | 塞勒克提斯公司 | 工程化异体和免疫抑制耐受性t细胞的方法 |
| WO2014011993A2 (en) | 2012-07-13 | 2014-01-16 | The Trustees Of The University Of Pennsylvania | Epitope spreading associated with car t-cells |
| EP3584256A1 (en) | 2012-07-13 | 2019-12-25 | The Trustees Of The University Of Pennsylvania | Methods of assessing the suitability of transduced t cells for administration |
| CA2876730A1 (en) | 2012-07-13 | 2014-01-16 | The Trustees Of The University Of Pennsylvania | Enhancing activity of car t cells by co-introducing a bispecific antibody |
| IL293944A (en) | 2012-08-20 | 2022-08-01 | Hutchinson Fred Cancer Res | Method and preparations for cellular immunotherapy |
| EP2900695B1 (en) | 2012-09-27 | 2018-01-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin antibodies and methods for eliciting potent antitumor activity |
| AR092745A1 (es) | 2012-10-01 | 2015-04-29 | Univ Pennsylvania | Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer |
| KR102198058B1 (ko) | 2012-10-02 | 2021-01-06 | 메모리얼 슬로안 케터링 캔서 센터 | 면역치료용 조성물 및 방법 |
| US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| CN104271602B (zh) | 2012-11-21 | 2020-08-21 | 武汉友芝友生物制药有限公司 | 双特异性抗体 |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| US20150329640A1 (en) | 2012-12-20 | 2015-11-19 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
| EP2953974B1 (en) | 2013-02-05 | 2017-12-20 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and bcma |
| KR102417657B1 (ko) | 2013-02-06 | 2022-07-07 | 안트로제네시스 코포레이션 | 개선된 특이성을 갖는 변경된 t 림프구 |
| KR102332790B1 (ko) | 2013-02-15 | 2021-12-01 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 키메라 항원 수용체 및 이의 이용 방법 |
| EP3744736A1 (en) | 2013-02-20 | 2020-12-02 | Novartis AG | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| KR102363191B1 (ko) | 2013-02-26 | 2022-02-17 | 메모리얼 슬로안 케터링 캔서 센터 | 면역치료용 조성물 및 방법 |
| CN105143270B (zh) | 2013-02-26 | 2019-11-12 | 罗切格利卡特公司 | 双特异性t细胞活化抗原结合分子 |
| US9393257B2 (en) | 2013-03-01 | 2016-07-19 | Regents Of The University Of Minnesota | TALEN-based gene correction |
| EP2964675B1 (en) | 2013-03-05 | 2018-06-20 | Baylor College Of Medicine | Engager cells for immunotherapy |
| WO2014138704A1 (en) * | 2013-03-07 | 2014-09-12 | Baylor College Of Medicine | Targeting cd138 in cancer |
| CN105518018B (zh) | 2013-03-15 | 2020-04-03 | 细胞基因公司 | 修饰的t淋巴细胞 |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| CA2904265C (en) | 2013-03-15 | 2023-08-08 | Victor D. FEDOROV | Compositions and methods for immunotherapy |
| US9446105B2 (en) | 2013-03-15 | 2016-09-20 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor specific for folate receptor β |
| US10150800B2 (en) | 2013-03-15 | 2018-12-11 | Zyngenia, Inc. | EGFR-binding modular recognition domains |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| CA3185368A1 (en) | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t cells derived from pluripotent stem cells |
| US11311575B2 (en) | 2013-05-13 | 2022-04-26 | Cellectis | Methods for engineering highly active T cell for immunotherapy |
| RU2727447C2 (ru) | 2013-05-13 | 2020-07-21 | Селлектис | Cd19-специфический химерный антигенный рецептор и его применения |
| EP3004168A4 (en) | 2013-05-24 | 2017-03-01 | Board of Regents, The University of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| ES2883131T3 (es) | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| EP3309248B1 (en) | 2013-05-29 | 2021-06-09 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| AU2014287011A1 (en) | 2013-07-12 | 2016-02-25 | Zymeworks Inc. | Bispecific CD3 and CD19 antigen binding constructs |
| EP3027755B1 (en) | 2013-08-02 | 2019-10-09 | The Regents of The University of California | Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors |
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| US20150238631A1 (en) | 2013-10-15 | 2015-08-27 | The California Institute For Biomedical Research | Chimeric antigen receptor t cell switches and uses thereof |
| CN105829349B (zh) | 2013-10-15 | 2023-02-03 | 斯克利普斯研究所 | 肽嵌合抗原受体t细胞开关和其用途 |
| PT3083671T (pt) | 2013-12-20 | 2020-12-24 | Hutchinson Fred Cancer Res | Moléculas efetoras quiméricas etiquetadas e recetores destas |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| JP2017504601A (ja) | 2013-12-20 | 2017-02-09 | セレクティスＣｅｌｌｅｃｔｉｓ | 免疫療法のためにマルチインプットシグナル感受性ｔ細胞を操作する方法 |
| DK3089994T3 (da) | 2013-12-30 | 2022-07-04 | Epimab Biotherapeutics Inc | Fabs-in-tandem-immunglobulin og anvendelser deraf |
| AU2015206040B2 (en) | 2014-01-14 | 2018-11-01 | Cellectis | Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish |
| US11028143B2 (en) | 2014-01-21 | 2021-06-08 | Novartis Ag | Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| EP3097123A1 (en) | 2014-01-24 | 2016-11-30 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-ny-br-1 polypeptides, proteins, and chimeric antigen receptors |
| RS66199B1 (sr) | 2014-02-04 | 2024-12-31 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | Metode za proizvodnju autolognih t ćelija koje su korisne za lečenje b ćelijskih maligniteta i drugih karcinoma i njihove kompozicije |
| CA2937711C (en) | 2014-02-14 | 2020-10-20 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| MX369513B (es) | 2014-02-14 | 2019-11-11 | Univ Texas | Receptores de antígenos quiméricos y métodos de realización. |
| US10196608B2 (en) | 2014-02-21 | 2019-02-05 | Cellectis | Method for in situ inhibition of regulatory T cells |
| CN106029098A (zh) | 2014-02-25 | 2016-10-12 | 免疫医疗公司 | 人源化rfb4抗cd22抗体 |
| KR101605421B1 (ko) | 2014-03-05 | 2016-03-23 | 국립암센터 | B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도 |
| EP3811970A1 (en) | 2014-03-15 | 2021-04-28 | Novartis AG | Regulatable chimeric antigen receptor |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| JP6698546B2 (ja) | 2014-04-14 | 2020-05-27 | セレクティスＣｅｌｌｅｃｔｉｓ | 癌免疫療法のためのｂｃｍａ（ｃｄ２６９）特異的キメラ抗原受容体 |
| RS60544B1 (sr) | 2014-04-25 | 2020-08-31 | Bluebird Bio Inc | Poboljšani metodi za proizvodnju adoptivnih ćelijskih terapija |
| CN107074929B (zh) | 2014-05-02 | 2021-09-03 | 宾夕法尼亚大学董事会 | 嵌合自身抗体受体t细胞的组合物和方法 |
| CN106535925A (zh) | 2014-05-23 | 2017-03-22 | 佛罗里达大学研究基金会有限公司 | 基于car的免疫治疗 |
| WO2015177349A1 (en) | 2014-05-23 | 2015-11-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti- egfr conformational single domain antibodies and uses thereof |
| JP2017518053A (ja) | 2014-06-06 | 2017-07-06 | メモリアル スローン−ケタリング キャンサー センター | メソセリン標的化キメラ抗原受容体およびその使用 |
| KR20170032406A (ko) | 2014-07-15 | 2017-03-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료를 위한 조작된 세포 |
| JP7054622B2 (ja) * | 2014-07-21 | 2022-04-14 | ノバルティス アーゲー | ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置 |
| EP3172231B1 (en) | 2014-07-24 | 2021-05-05 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| MX367787B (es) | 2014-07-29 | 2019-09-06 | Cellectis | Receptores de antígenos quimericos ror1 (ntrkr1) específicos para inmunoterapia del cáncer. |
| EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| US9994817B2 (en) | 2014-08-07 | 2018-06-12 | Northwestern University | Use of ligands for the programmed cell death receptor conjugated to solid supports for cultivating human regulatory T cells |
| ES2819451T3 (es) | 2014-08-08 | 2021-04-16 | Univ Leland Stanford Junior | Agentes PD-1 de alta afinidad y procedimientos de uso |
| WO2016019969A1 (en) | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universität München | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
| JP2017524365A (ja) | 2014-08-12 | 2017-08-31 | アントフロゲネシス コーポレーション | リンパ節のｂ細胞領域、皮膚、または腸管にホーミングするように操作されたｃａｒ−ｔ細胞 |
| ES3034398T3 (en) | 2014-08-28 | 2025-08-18 | Bioatla Inc | Conditionally active chimeric antigen receptors for modified t-cells |
| GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
| WO2016036678A1 (en) | 2014-09-02 | 2016-03-10 | Medimmune, Llc | Formulations of bispecific antibodies |
| JP2017527310A (ja) | 2014-09-09 | 2017-09-21 | ユーナム・セラピューティクスＵｎｕｍ Ｔｈｅｒａｐｅｕｔｉｃｓ | キメラ受容体および免疫療法におけるその使用 |
| AU2015317351B2 (en) | 2014-09-19 | 2020-07-02 | City Of Hope | Costimulatory chimeric antigen receptor T cells targeting IL3Ra2 |
| WO2016054520A2 (en) | 2014-10-03 | 2016-04-07 | The California Institute For Biomedical Research | Engineered cell surface proteins and uses thereof |
| CN107109368A (zh) | 2014-10-07 | 2017-08-29 | 塞勒克提斯公司 | 用于调节car诱导的免疫细胞活性的方法 |
| SG11201703203RA (en) | 2014-10-20 | 2017-05-30 | Juno Therapeutics Inc | Methods and compositions for dosing in adoptive cell therapy |
| HK1243333A1 (zh) | 2014-10-31 | 2018-07-13 | The Trustees Of The University Of Pennsylvania | 用於修饰的t细胞的方法和组合物 |
| US10688166B2 (en) | 2014-11-03 | 2020-06-23 | Cerus Corporation | Compositions and methods for improved car-T cell therapies |
| HUE050264T2 (hu) | 2014-11-05 | 2020-11-30 | Juno Therapeutics Inc | Eljárások transzdukálásra és sejtfeldolgozásra |
| WO2016081518A2 (en) | 2014-11-17 | 2016-05-26 | Adicet Bio, Inc. | Engineered gamma delta t-cells |
| EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| PL3221357T3 (pl) | 2014-11-20 | 2020-11-02 | F. Hoffmann-La Roche Ag | Wspólne łańcuchy lekkie i sposoby zastosowania |
| EP3025719B1 (en) | 2014-11-26 | 2018-09-26 | Miltenyi Biotec GmbH | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases |
| EP3029067A1 (en) | 2014-12-01 | 2016-06-08 | Deutsches Krebsforschungszentrum | Use of blocking-reagents for reducing unspecific T cell-activation |
| JP7068820B2 (ja) | 2014-12-03 | 2022-05-17 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法のための方法および組成物 |
| EP3029068A1 (en) | 2014-12-03 | 2016-06-08 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases |
| US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
| EP3227339B1 (en) | 2014-12-05 | 2021-11-10 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof |
| KR102701479B1 (ko) | 2014-12-05 | 2024-09-03 | 메모리얼 슬로안 케터링 캔서 센터 | B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법 |
| EP3227432B1 (en) | 2014-12-05 | 2023-10-11 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
| EP3233095A2 (en) | 2014-12-17 | 2017-10-25 | Cellectis | INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN |
| EP3037170A1 (en) | 2014-12-27 | 2016-06-29 | Miltenyi Biotec GmbH | Multisort cell separation method |
| WO2016109410A2 (en) | 2014-12-29 | 2016-07-07 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| JP2018503399A (ja) | 2015-01-14 | 2018-02-08 | コンパス セラピューティクス リミテッド ライアビリティ カンパニー | 多特異性免疫調節抗原結合構築物 |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| TWI718118B (zh) | 2015-01-16 | 2021-02-11 | 美商奇諾治療有限公司 | 針對ｒｏｒ１之特異性抗體及嵌合抗原受體 |
| GB201501175D0 (en) | 2015-01-23 | 2015-03-11 | Univ Oslo Hf | A universal T-cell for personalised medicine |
| EP3250611B1 (en) | 2015-01-26 | 2021-04-21 | The University of Chicago | Car t-cells recognizing cancer-specific il 13r-alpha2 |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| AU2016215110A1 (en) | 2015-02-05 | 2017-09-21 | Stc.Unm | Anti-pre-BCR antagonists and methods |
| AU2016214978B2 (en) | 2015-02-05 | 2021-12-09 | The University Of Queensland | Targeting constructs for delivery of payloads |
| US20160228547A1 (en) | 2015-02-06 | 2016-08-11 | Batu Biologics, Inc. | Chimeric antigen receptor targeting of tumor endothelium |
| EP3256492A4 (en) * | 2015-02-09 | 2018-07-11 | University of Florida Research Foundation, Inc. | Bi-specific chimeric antigen receptor and uses thereof |
| EP3256496B1 (en) | 2015-02-12 | 2020-12-30 | University Health Network | Chimeric antigen receptors |
| US20160237407A1 (en) | 2015-02-17 | 2016-08-18 | Batu Biologics, Inc. | Universal donor chimeric antigen receptor cells |
| JP6858128B2 (ja) | 2015-02-18 | 2021-04-14 | エンリヴェックス セラピューティクス リミテッド | 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ |
| WO2016138034A1 (en) | 2015-02-24 | 2016-09-01 | The Regents Of The University Of California | Binding-triggered transcriptional switches and methods of use thereof |
| IL254141B (en) * | 2015-02-27 | 2022-07-01 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars) focusing on hematological malignancies, preparations and methods for their use |
| EP3089761B1 (en) | 2015-03-02 | 2019-06-12 | Innovative Cellular Therapeutics Co., Ltd. | Reducing immune tolerance induced by pd l1 |
| SG10201908203SA (en) | 2015-03-05 | 2019-10-30 | Hutchinson Fred Cancer Res | Immunomodulatory Fusion Proteins And Uses Thereof |
| GB201504840D0 (en) | 2015-03-23 | 2015-05-06 | Ucl Business Plc | Chimeric antigen receptor |
| US11261232B2 (en) | 2015-04-02 | 2022-03-01 | Memorial Sloan Kettering Cancer Center | TNFRSF14 / HVEM proteins and methods of use thereof |
| DK3298033T4 (da) | 2015-05-18 | 2023-10-02 | Tcr2 Therapeutics Inc | Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner |
| CA2989949A1 (en) | 2015-06-19 | 2016-12-22 | Sebastian KOBOLD | Pd-1-cd28 fusion proteins and their use in medicine |
| KR20180019725A (ko) | 2015-06-23 | 2018-02-26 | 메모리얼 슬로안-케터링 캔서 센터 | 신규의 피디 1 면역 조절제 |
| US11173179B2 (en) * | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| TW202444897A (zh) * | 2015-06-25 | 2024-11-16 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體(car)、組合物及其使用方法 |
| KR20180038447A (ko) | 2015-06-29 | 2018-04-16 | 더 존스 홉킨스 유니버시티 | 면역 체크포인트 키메라 수용체 치료법 |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| HK1258041A1 (zh) | 2015-09-04 | 2019-11-01 | 纪念斯隆-凯特林癌症中心 | 免疫细胞组合物和使用方法 |
| JP6816133B2 (ja) | 2015-10-05 | 2021-01-20 | プレシジョン バイオサイエンシズ，インク． | 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞 |
| US11020429B2 (en) | 2015-11-05 | 2021-06-01 | Juno Therapeutics, Inc. | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy |
| CN105331585A (zh) | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| CN109072194B (zh) | 2015-12-09 | 2022-12-27 | 纪念斯隆-凯特林癌症中心 | 免疫细胞组合物及其使用方法 |
| WO2017112741A1 (en) | 2015-12-22 | 2017-06-29 | Novartis Ag | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
| EP4286522A3 (en) | 2016-03-23 | 2024-02-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| CN109328074A (zh) | 2016-04-01 | 2019-02-12 | 凯德药业股份有限公司 | 嵌合抗原和t细胞受体及使用的方法 |
| EP4371570A3 (en) | 2016-06-08 | 2024-07-17 | Xencor, Inc. | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
| JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法 |
| EP3507361A1 (en) | 2016-08-30 | 2019-07-10 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use for treating viral and other infections |
| CA3036745A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| AU2017382902A1 (en) | 2016-12-21 | 2019-07-18 | TCR2 Therapeutics Inc. | Engineered T cells for the treatment of cancer |
| EP3525805A4 (en) | 2016-12-22 | 2020-07-29 | Windmil Therapeutics, Inc. | COMPOSITIONS AND METHODS OF MODULATION OF THE IMMUNE SYSTEM |
| CN108341872B (zh) | 2017-01-23 | 2020-05-19 | 科济生物医药（上海）有限公司 | 靶向bcma的抗体及其应用 |
| IL310182A (en) | 2017-04-26 | 2024-03-01 | Eureka Therapeutics Inc ׂ A Delaware Corp | Structures of chimeric antibody/T-cell receptor and uses thereof |
| EP3638295A1 (en) | 2017-06-13 | 2020-04-22 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CN111212663A (zh) | 2017-07-07 | 2020-05-29 | H·李·莫菲特癌症中心研究所公司 | 具有突变的cd28共刺激性结构域的嵌合抗原受体 |
| EP3684424A4 (en) | 2017-09-22 | 2021-09-29 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | ENHANCED NFKB SIGNALING CHEMERICAL ANTIGENIC RECEPTORS |
| CN112041335A (zh) | 2018-02-26 | 2020-12-04 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的组合物和方法 |
| WO2019173693A1 (en) | 2018-03-09 | 2019-09-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2019222275A2 (en) | 2018-05-14 | 2019-11-21 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using inducible fusion proteins |
| JP2021530503A (ja) | 2018-07-26 | 2021-11-11 | ティーシーアール２ セラピューティクス インク． | 標的特異的融合タンパク質を使用してｔｃｒをリプログラミングするための組成物及び方法 |
| TW202026006A (zh) | 2018-08-30 | 2020-07-16 | 美商Ｔｃｒ２療法股份有限公司 | 使用融合蛋白進行tcr再程式化之組成物及方法 |
-
2017
- 2017-11-22 CA CA3044593A patent/CA3044593A1/en active Pending
- 2017-11-22 AU AU2017363311A patent/AU2017363311A1/en not_active Abandoned
- 2017-11-22 US US16/462,492 patent/US11851491B2/en active Active
- 2017-11-22 CN CN201780083288.5A patent/CN110177803A/zh active Pending
- 2017-11-22 JP JP2019527363A patent/JP7291396B2/ja active Active
- 2017-11-22 WO PCT/US2017/063137 patent/WO2018098365A2/en not_active Ceased
- 2017-11-22 EP EP17812183.6A patent/EP3544996A2/en not_active Withdrawn
-
2023
- 2023-05-29 JP JP2023087484A patent/JP2023109968A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN110177803A (zh) | 2019-08-27 |
| US11851491B2 (en) | 2023-12-26 |
| WO2018098365A3 (en) | 2018-07-12 |
| AU2017363311A1 (en) | 2019-06-13 |
| JP7291396B2 (ja) | 2023-06-15 |
| WO2018098365A2 (en) | 2018-05-31 |
| JP2019536452A (ja) | 2019-12-19 |
| EP3544996A2 (en) | 2019-10-02 |
| JP2023109968A (ja) | 2023-08-08 |
| US20190276540A1 (en) | 2019-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11851491B2 (en) | Compositions and methods for TCR reprogramming using fusion proteins | |
| US11085021B2 (en) | Compositions and methods for TCR reprogramming using fusion proteins | |
| US11242376B2 (en) | Compositions and methods for TCR reprogramming using fusion proteins | |
| EP3298033B1 (en) | Compositions and medical uses for tcr reprogramming using fusion proteins | |
| WO2019222275A2 (en) | Compositions and methods for tcr reprogramming using inducible fusion proteins | |
| US20210187022A1 (en) | Engineered t cells for the treatment of cancer | |
| US20210253666A1 (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| HK40045811A (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| HK40008051A (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| HK40007902A (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| HK1252643B (en) | Compositions and medical uses for tcr reprogramming using fusion proteins | |
| EA043737B1 (ru) | Композиции и способы репрограммирования т-клеточных рецепторов с помощью гибридных белков |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220928 |
|
| EEER | Examination request |
Effective date: 20220928 |